Metraipolis › archive › dc_9feed6152ada

Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease — Europe PMC PMID:41463563

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41463563
DOI: 10.3390/biology14121790
License (as archived): solo-consultazione
Archived: 2026-11-07T15:24:03.846Z
SHA-256 of the archived text: 791af0440e167f6a0596917ffeb7a3120ec2439c06eb6bc8f0069cf8a28159ef
Stable URL of this page: https://metraipolis.com/documento/dc_9feed6152ada

How to cite

Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease — Europe PMC PMID:41463563 — Europe PMC (en), https://europepmc.org/article/MED/41463563 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9feed6152ada (Metraipolis archive dc_9feed6152ada, sha256 791af0440e167f6a0596917ffeb7a3120ec2439c06eb6bc8f0069cf8a28159ef)

BibTeX

@misc{dc9feed6152ada,
  title = {Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease — Europe PMC PMID:41463563},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41463563},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9feed6152ada; sha256 791af0440e167f6a0596917ffeb7a3120ec2439c06eb6bc8f0069cf8a28159ef},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41463563. Agents can read the archived copy with the MCP tool read_document.